The effects of hexahydrocurcumin on adenosine diphosphate (ADP)-induced human platelet aggregation were studied. Treatment of human platelet-rich plasma with hexahydrocurcumin resulted in an inhibitory effect on platelet aggregation, suggesting the potential of this compound as an anti-atherosclerogenic agent in humans.
Ginger (Zingiber officinale Roscoe) is a common condiment for various foods and beverages. The underground stem or rhizome of this plant has been used as a medicine in Asian, Indian, Chinese and Arabic herbal traditions since ancient time. The non-volatile pungent ingredients from ginger include gingerol, shoagol, and zingerone. Recently, several population-based studies showed that people in South East Asian countries have a much lower risk of colon, gastro-intestinal, prostate, breast, and other cancers than European and American countries. It is believed that constituents of their dietary supplements may play an important role in this protection [1a] .
In both in vitro and in vivo experimental carcinogenesis, curcumin derivatives have been shown to possess cancer preventive activities [1a-1f] . These compounds are known to have the ability to suppress the transformative, hyperproliferative, and inflammatory processes of carcinogenesis. Curcumin derivatives have a wide range of therapeutic applications and have protective activity against inflammation and cancer. However, no study has been made on the aggregative effect of hexahydrocurcumin on human platelets.
Hexahydrocurcumin, (5S)-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3-one [1g], suppresses the activity of nitric oxide synthase through down-regulation of IκB kinase and NFκB activation in macrophages [1h]. Different natural products, such as gingerols and shogaols, have been found to induce cell death in malignant cells [1b-1e]. To elucidate the aggregative effect of hexahydrocurcumin, platelet-rich human whole blood was used. Platelets were treated with 0.5, 1, 2 and 3 μg/μL hexahydrocurcumin for 5 minutes before the addition of adenosine diphosphate (ADP). The aggregation ability of human platelets was decreased in a concentration-dependent manner (Figure 1 ; n = 5). This suggests that hexahydrocurcumin is appropriate for consideration as an anti-platelet aggregation drug and antiatherosclerogenic agent in humans. hexahydrocurcumin Figure 1 : Effects of hexahydrocurcumin on platelet aggregation. Platelet-rich plasma (PRP) was incubated with hexahydrocurcumin (0.5, 1, 2 and 3 μg/μL) for 5 mins before ADP was added. PRP was triggered by ADP and the aggregation ability was measured using an aggregometer. ** Significantly different from control, p < 0.01. *** Significantly different from control, p < 0.001.
Experimental
Reagents and materials: ADP was obtained from Sigma (St. Louis, MO, USA), and hexahydrocurcumin was extracted from Z. officinale (ginger), as described previously [2] . The compound was identified by spectroscopic data analysis and comparison with literature values.
In vitro experiments:
Human blood samples were obtained on the day of the experiment from volunteers who had taken no medication in the previous 4 weeks. Blood samples were drawn from the vein and collected in a tube that contained sodium citrate (3.8%; 1 volume for 9 volumes of blood). The blood was collected and utilized within 2.5 h. 
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Detection of platelet aggregation:
Platelet-rich plasma (PRP) with a leukocyte count of 0-100/μL was prepared by centrifugation at 1,000 rpm for 10 mins at room temperature. Platelet-poor plasma (PPP) was prepared by centrifugation at 3,000 rpm for 10 mins. Platelet count was determined by an electronic counter (Sysmex microcellcounter F-800; Toa Medical Electronics, Kobe, Japan). The platelet count of the PRP was adjusted to 400,000/μL by dilution with platelet-poor plasma (PPP), as needed [3a-3c] . Platelet aggregation in PRP was induced by addition of 5 μM ADP and measured with an aggregometer (PACKS-4 platelet aggregation chromogenic kinetic system; Helena Laboratories, Beaumont, TX, USA). The tests were performed at 37°C with 250 μL PRP in a siliconized cuvette with continuous stirring. Hexahydrocurcumin (0.5, 1, 2 and 3 ug/uL) was added to the reaction tube after incubation with platelets for 5 mins before triggering by addition of 5 μM ADP.
Statistical analysis:
The data for platelet aggregation were presented as percentage aggregation relative to PPP. Data were expressed as mean ± standard error of the mean. Significance was determined by the t test and p < 0.05 was considered to be statistically significant.
